Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine in Patients With Supraventricular Tachycardia and Atrial Fibrillation
NCT02095405Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Feb 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of caffeine in supraventricular tachycardia (SVT) and Atrial fibrillation (AFib), sponsored by University of Ottawa Heart Institute. Primary endpoints: Refractory period of the Right Ventricle at 1 day and Refractory period of the Right Atrium at 1 day. Started Feb 2010; status: completed.
02
Drugs
caffeine
03
Conditions
supraventricular tachycardia (SVT)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02095405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095405.